Screener
Kymera Therapeutics KYMR Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
FAQ
- What is Kymera Therapeutics's enterprise value?
- Kymera Therapeutics (KYMR) reported enterprise value of $9.39B in Q2 2026.
- How has Kymera Therapeutics's enterprise value changed year-over-year?
- Kymera Therapeutics's enterprise value increased by 232.7% year-over-year, from $2.82B to $9.39B.
- What is the long-term trend for Kymera Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), Kymera Therapeutics's enterprise value has grown at a 16.6% compound annual growth rate (CAGR), from $2.76B to $5.95B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Kymera Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude